CoorsTek, Indo-MIM, Kl?ger Spritzguss, MICRO, Morgan Advanced M – Talented India - micro molding companies

A biosimilar with an interchangeable designation, which is designated by the FDA, may be auto-substituted for the reference product by a pharmacist. Individual state laws control how and whether providers and patients must be notified. An interchangeable biosimilar first must meet the high FDA standards of a biosimilar. Then, to achieve the interchangeable designation, the FDA requires additional data, which may include a study of multiple substitutions in patients, known as a switching study. The study must show that patients can be switched with no increased risk in terms of safety or diminished efficacy compared with remaining on the reference product in any given patient.

Boehringer Ingelheim and GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., announced today a patient affordability...

"We are pleased to be working with Boehringer Ingelheim to bring adalimumab-adbm to more patients. Our intent is to offer a copay assistance program, which will provide eligible patients access," said John Caulfield, President of Quallent Pharmaceuticals Health, LLC. "Quallent was established to help pharmacies give their patients safe and affordable medication, and this collaboration will help us deliver on this goal."

In-machine deflashing with center-of-machine scrap removal that keeps the conveyor behind the clamping/molding stations and allows more space for mold changes and maintenance.

W. Müller’s new melt filtration technology — the WM-096 Manual Screen Changer System, housed between the main extruder and die-head.

The RBS-E550D is constructed  of heavy-walled steel tubes and a steel plate frame and features a walk-in molding area and top-of-machine access platforms strong enough to mount a mold-changing crane.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The new all-electric shuttle brings a smaller footprint, flexibility, and efficiency to demanding packaging applications.

Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the Cyltezo® trademark under license. The other trademarks referenced above are owned by third parties not affiliated with Boehringer Ingelheim Pharmaceuticals, Inc.

“This new shuttle expands our all-electric offering and gives customers another option that provides a smaller footprint, flexibility, and greater efficiency to meet today’s demanding packaging requirements,” said Fred Piercy, president and general manager of R&B.

You should discuss the potential benefits and risks of Adalimumab-adbm with your doctor. Adalimumab-adbm is a TNF-blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking Adalimumab-adbm if you have any kind of infection unless your doctor says it is okay.

*For more information on interchangeability for adalimumab-adbm, please refer to the Purple Book: https://purplebooksearch.fda.gov/.

Please see CYLTEZO Prescribing Information, including BOXED WARNING, and Medication Guide; and Adalimumab-adbm Prescribing Information, including BOXED WARNING and Medication Guide.

The latest all-electric extrusion blow molding (EBM) shuttle model from Michigan’s R&B Plastics Machinery will be showcased at NPE2024, as the company’s first such unit to feature Yaskawa X absolute servo-motors and drives.

The most common side effects of Adalimumab-adbm include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, and rash. These are not all the possible side effects with Adalimumab-adbm. Tell your doctor if you have any side effect that bothers you or that does not go away.

Also at R&B’s booth will be a static display of its standard 3-1/2-inch x 32:1 L/D MAX extruders with a vented-to-atmosphere barrel and standard Allen-Bradley Compact Logix-based controls with 15-inch TFT touchscreen.

Boehringer Ingelheim is one of the largest producers of biologic medicines in the world, producing biologic medicines to support our diverse pipeline, as well as other companies' biopharmaceuticals on a contract basis. As a pioneer in biologics, to date, Boehringer Ingelheim's Biopharmaceutical Contract Manufacturing business has supported our customers to bring dozens of biologics to the market in therapeutic areas that include oncology, immunology and cardiovascular indications. For more information about Boehringer Ingelheim's Biopharma and manufacturing capabilities, please click here: https://www.boehringer-ingelheim.com/us/biopharma/biosimilars.

Geoff Giordano is a tech journalist with more than 30 years’ experience in all facets of publishing. He has reported extensively on the gamut of plastics manufacturing technologies and issues, including 3D printing materials and methods; injection, blow, micro and rotomolding; additives, colorants and nanomodifiers; blown and cast films; packaging; thermoforming; tooling; ancillary equipment; and the circular economy. Contact him at [email protected].

"Boehringer Ingelheim is dedicated to broadening access to essential biologic medicines, and our collaboration with Quallent will increase availability of our adalimumab biosimilar for patients living with certain chronic inflammatory diseases," said Chris Marsh, Senior Vice President of Value and Access at Boehringer Ingelheim. "The utilization of biosimilars such as adalimumab-adbm provides the potential for more patients to benefit from biologic medicines and saves costs for both patients and the U.S. healthcare system overall. We're committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options."

At NPE, R&B’s Model RBS-E550D will be set up for a trilayer application designed for processing PE-type regrind resins. The demonstration will utilize a main extruder of 100 mm x 26:1 L/D ratio and satellite extruders of 70 mm x 24:1 L/D ratio for inner and outer layers.

RIDGEFIELD, Conn., May 13, 2024 /PRNewswire/ -- Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer's biosimilar to Humira® (adalimumab), in the U.S.

Visit R&B Plastics Machinery at booth S19071 during NPE2024 at the Orange County Convention Center in Orlando, FL, from May 6 to 10.

Boehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available....

In-machine servo-electric part takeout system with a center-of-machine takeaway conveyor that provides for a single-point container exit.

Please see CYLTEZO Prescribing Information, including BOXED WARNING, and Medication Guide; and Adalimumab-adbm Prescribing Information, including BOXED WARNING and Medication Guide.

These are not all the possible side effects of Adalimumab-adbm. For more information, speak with your doctor or pharmacist.

About Boehringer Ingelheim in Biologics and BiosimilarsThrough novel biologics and our biosimilar, we strive to increase the availability of safe, effective, high-quality therapeutic options to patients worldwide.

Quallent will be offering both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) citrate-free formulations of adalimumab-adbm as a pre-filled syringe or pen. Adalimumab-adbm's interchangeability designation* for the low-concentration formulation will extend to Quallent's 40 mg/0.8 mL private-labeled adalimumab-adbm.

About BiosimilarsA biosimilar is a biologic medicine that is developed to be highly similar to an approved reference biologic, with no clinically meaningful differences in terms of safety, potency and purity.

Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo® (adalimumab-adbm) injection and Adalimumab-adbm.

About Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Discover more at www.boehringer-ingelheim.com/us.

Also tell your doctor about all the medicines you take. You should not take Adalimumab-adbm with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).